Chimerix to Present at Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its participation in the Targeted Oncology panel at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 10:20 a.m. During this event, the management will discuss their mission to develop life-extending medicines for patients facing deadly diseases. A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website, where it will remain archived for approximately 90 days.

Chimerix's advanced development program focuses on ONC201 for H3 K27M-mutant glioma.

News Market Reaction – CMRX

+4.78%

+4.78% Session move

In the trading session that priced this news, CMRX gained 4.78%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:
        
Michelle LaSpaluto
919 972-7115
ir@chimerix.com 

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

What is the date of Chimerix's presentation at the Wedbush PacGrow Healthcare Conference?

Chimerix will present on August 9, 2022, at 10:20 a.m.

Where can I find the webcast of Chimerix’s presentation?

The webcast will be available on the Investor Relations section of Chimerix’s website and archived for approximately 90 days.

What is Chimerix's primary focus in developing medicines?

Chimerix focuses on developing medicines that improve and extend the lives of patients facing deadly diseases.

Which program is Chimerix's most advanced clinical-stage development program?

Chimerix's most advanced program is ONC201, aimed at treating H3 K27M-mutant glioma.